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(lPs)-activated Macrophages but 
Does not affect lPs-Driven cytokine 
Production or Toll-like receptor 4 
endocytosis
Manjula Nagala1, Emma McKenzie1, Hannah Richards1, Ritu Sharma1, Sarah Thomson1, 
Pietro Mastroeni2 and Paul R. Crocker1*
1 Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, United Kingdom, 
2 Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
Siglec-E is a murine CD33-related siglec that functions as an inhibitory receptor and is 
expressed mainly on neutrophils and macrophage populations. Recent studies have 
suggested that siglec-E is an important negative regulator of lipopolysaccharide (LPS)-
toll-like receptor 4 (TLR4) signaling and one report (1) claimed that siglec-E is required for 
TLR4 endocytosis following uptake of Escherichia coli by macrophages and dendritic cells 
(DCs). Our attempts to reproduce these observations using cells from wild-type (WT) and 
siglec-E-deficient mice were unsuccessful. We used a variety of assays to determine if siglec-E 
expressed by different macrophage populations can regulate TLR4 signaling in response to 
LPS, but found no consistent differences in cytokine secretion in vitro and in vivo, comparing 
three different strains of siglec-E-deficient mice with matched WT controls. No evidence 
was found that the siglec-E deficiency was compensated by expression of siglecs-F and -G, 
the other murine inhibitory CD33-related siglecs. Quantitative proteomics was used as 
an unbiased approach and provided additional evidence that siglec-E does not suppress 
inflammatory TLR4 signaling. Interestingly, proteomics revealed a siglec-E-dependent 
alteration in macrophage protein composition that could be relevant to functional responses 
in host defense. In support of this, siglec-E-deficient mice exhibited enhanced growth of 
Salmonella enterica serovar Typhimurium in the liver following intravenous infection, but 
macrophages lacking siglec-E did not show altered uptake or killing of bacteria in vitro. 
Using various cell types including bone marrow-derived DCs (BMDCs), splenic DCs, and 
macrophages from WT and siglec-E-deficient mice, we showed that siglec-E is not required 
for TLR4 endocytosis following E. coli uptake or LPS challenge. We failed to see expression 
of siglec-E by BMDC even after LPS-induced maturation, but confirmed previous studies 
that splenic DCs express low levels of siglec-E. Taken together, our findings do not support 
a major role of siglec-E in regulation of TLR4 signaling functions or TLR4 endocytosis in 
macrophages or DCs. Instead, they reveal that induction of siglec-E by LPS can modulate 
the phenotype of macrophages, the functional significance of which is currently unclear.
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inTrODUcTiOn
Innate immune cells express toll-like receptors (TLRs) which 
play critical roles in recognition of various pathogen-associated 
molecular patterns (PAMPs). Exposure of macrophages and 
dendritic cells (DCs) to PAMPS, such as Gram-negative bacte-
rial lipopolysaccharide (LPS), which triggers through TLR4, 
can orchestrate a diverse gene expression program required for 
shaping the innate and adaptive arms of the immune response 
(2–4). These changes include the induction or repression of a 
wide range of genes that regulate pro-inflammatory cytokines, 
chemokines, inflammatory mediators, polarization, migration, 
and cell survival. These processes are tightly regulated and loss 
of control is associated with conditions, such as septic shock and 
inflammatory diseases (5–7).
Many immune cells express a variety of membrane proteins 
with cytosolic tyrosine-based inhibitory motifs (ITIMs) that 
negatively regulate signaling through activation receptors. 
One important class of such inhibitory receptors implicated 
in regulation of TLR signaling is the family of siglecs, defined 
as transmembrane sialic acid-binding Ig-like lectins (8). The 
CD33-related siglecs are a recently evolved subset that are 
mainly expressed in a complex manner by cells of the innate 
immune system. Most contain an ITIM and an ITIM-like motif 
in their cytoplasmic tails which, following tyrosine phospho-
rylation by Src-family kinases, are thought to be important for 
inhibitory signaling via recruitment and activation of protein 
tyrosine phosphatases SHP-1 and SHP-2 (9, 10). The sialic acid-
binding sites of inhibitory siglecs on leukocytes are occupied 
by cis-interactions with sialic acids on the plasma membrane 
[reviewed in Ref. (8)]. Depending on the sialic acid carriers, 
these cis-interactions are likely to be important for regulating the 
functional responses of siglecs [reviewed in Ref. (11)]. Siglecs 
can also interact with sialic acid ligands in trans, for example, 
on encountering another cell or a pathogen expressing high-
affinity/avidity ligands and this can trigger siglec-dependent 
signaling functions and endocytosis.
As a model system to understand the signaling functions of 
inhibitory CD33-related siglecs on myeloid cells, our labora-
tory has focused on murine siglec-E which is mainly expressed 
on neutrophils, tissue macrophages, and splenic DCs (12, 13). 
There have been several reports showing that siglec-E and 
its human homolog siglec-9 are important for regulation of 
TLR4-driven cytokine production in macrophages and DCs. 
In murine bone marrow-derived macrophages (BMDM), 
cross-linking of siglec-E with antibodies (Abs) reduced the 
production of TNF-α, IL-6, and RANTES in response to LPS 
stimulation (14). Overexpression of recombinant human 
siglec-9 in human THP-1 and mouse RAW264 macrophage 
cell lines downregulated the production of pro-inflammatory 
cytokines following LPS stimulation (15). Siglec-E expres-
sion has been shown to suppress pro-inflammatory cytokine 
production by macrophages in response to a sialylated strain 
of Group B Streptococcus (16) and treatment of murine mac-
rophages with sialic acid-decorated nanoparticles was found to 
abrogate LPS-induced inflammation (17). More recently, Chen 
et  al. reported direct interactions between TLRs and siglecs, 
including siglec-E (18). The same group also proposed that 
cis-interactions between siglec-E and TLR-4 are required for 
TLR4 endocytosis following uptake of Escherichia coli and are 
important for downregulating TLR4-mediated inflammatory 
responses (1, 18).
In this report, we further investigate the potential role of 
siglec-E in TLR4 signaling via cis-interactions using three dif-
ferent lines of WT and siglec-E-deficient mice. Consistent with 
previous studies, we show that siglec-E is strongly upregulated 
by low-dose (1  ng/ml) LPS leading to constitutive tyrosine 
phosphorylation and recruitment of the negative regulator 
SHP-1. However, we were unable to demonstrate a siglec-E-
dependent effect on pro-inflammatory cytokine production by 
macrophages challenged with a high dose (100 ng/ml) of LPS, 
using a variety of approaches, including unbiased quantitative 
proteomics. Furthermore, we failed to see any expression of 
siglec-E on bone marrow-derived DCs (BMDCs) and were 
unable to reproduce the previous findings of siglec-E-dependent 
internalization of TLR4 in response to bacterial challenge. 
However, we could demonstrate by quantitative proteomics that 
the phenotype of siglec-E-deficient macrophages challenged 
with LPS was different from WT macrophages, suggesting 
that siglec-E contributes to the differentiation of macrophages 
exposed to LPS, but plays little or no role in directly regulat-
ing TLR4-dependent signaling by macrophages or DCs under 
physiological conditions.
MaTerials anD MeThODs
Materials
Dulbecco’s phosphate-buffered saline (PBS) without Ca and 
Mg, fetal bovine serum (FBS) (qualified, heat inactivated, E.U.-
approved), penicillin and streptomycin solution, Trypsin–EDTA 
solution, protein G Dynabeads, Microplate BCA Protein Assay, 
NuPAGE LDS Sample Buffer, NuPAGE® Novex 4–12% Bis-Tris 
gel, MOPS running buffer, and sample reducing agent, trypsin 
protease, Pierce MS Grade, TMT 10-plex™ Isobaric Reagent 
Label Set were from Thermo Fisher Scientific, Paisley, UK; Sera-
Mag SpeedBead Carboxylate-Modified Magnetic Particles were 
from GE LifeSciences; Roche-COMPLETE Mini EDTA-Free 
Protease Inhibitor tablets, Roche-PHOSS-RO, PhosSTOP™ 
Trypan blue solution, anti-sheep IgG (whole molecule)-
peroxidase and anti-rabbit IgG (whole molecule)–peroxidase Ab 
produced in goat, lipopolysaccharide from E. coli 0111:B4 were 
from Sigma; GM-CSF and IL-4 were from Peprotech, GolgiStop, 
CD16/CD32 (Fc block), V500 rat anti-mouse I-A/I-E (clone: 
M5/114; 562366) were from BD Bioscience, UK; anti-mouse 
TNF alpha PE (clone: MP6-XT22), anti-mouse CD11c PE-cy7 
(Clone: N418), anti-mouse Ly-6G (Gr-1) Alexa Fluor® 488 
(clone: RB6-8C5) were from eBioscience, UK; anti-Salmonella 
Typhimurium (clone: 1E6), anti-phosphotyrosine Ab (HRP) 
(Abcam clone: PY20-ab16389) were from Abcam, UK; APC 
anti-mouse CD11c Ab (clone: N418), PE-conjugated anti-siglec-
E used in flow cytometry (clone: M1304A01), biotin anti-mouse 
TLR4 (CD284)/MD2 complex Ab (clone: MTS510), PE/Cy7 
anti-mouse TLR4 (CD284)/MD2 complex Ab (clone: MTS510), 
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PE anti-mouse/human CD11b Ab (clone: M1/70), APC/Cy7 
anti-mouse Ly-6G/Ly-6C (Gr-1) Ab (clone: RB6-8C5) were 
from Biolegend, UK; and anti-mouse SHP-1 Ab (clone: C-19) 
was from Santa Cruz. E. coli 0111:B4 LPS (Sigma) was used 
in all in  vitro experiments. E. coli-GFP was obtained from the 
American Type Culture Collection (25922GFP). Affinity purified 
sheep anti-siglec-E Ab was produced in-house (12) and used for 
immunoprecipitation and immunoblotting and in flow cytometry 
experiments where indicated. Anti-mouse siglec-1 Abs SER-4 
and 3D6 were produced in-house (19, 20).
animals
Wild-type and siglec-E-deficient mice on C57BL/6J and Balb/c 
genetic backgrounds were generated as described previously 
(13, 21). Mice were bred and maintained under specific pathogen-
free conditions within our own institutional colonies. WT and 
siglec-E-deficient mice were derived from heterozygous intercrosses 
and then maintained through homozygous crosses between WT 
mice and siglec-E-deficient mice. Periodically, the homozygous 
mouse colonies were refreshed by heterozygous intercrossing. 
Mice used in experiments were sex- and age-matched between the 
ages of 7 and 24 weeks. Animal experimentation was approved by 
the University of Dundee Animal Ethics Committee and carried 
out under UK Home Office Project License PPL60/3856.
immunofluorescence staining
Cryostat sections of liver samples were prepared, fixed in pre-
cooled 100% methanol at −20°C, and blocked with 10% normal 
serum (Gibco) in 1% fish skin gelatin prior to addition of primary 
Abs and secondary Abs. Tissue sections were counterstained with 
400 ng/ml DAPI (Sigma), mounted in media (DAKOCytomation, 
USA) and analyzed by confocal microscopy. Excitation wave-
lengths were 405, 488, and 555  nm, and emission wavelengths 
maxima were 493/519 and 557/574 nm.
generation and stimulation of BMDMs
Bone marrow cells were cultured in bacteriological plastic 
Petri dishes with DMEM media supplemented with penicillin 
and streptomycin, glutamine, 10% FBS, and either 20% L929 
conditioned medium or M-CSF (25 ng/ml) for 7 days. BMDM 
were harvested with PBS supplemented with 3 mM EDTA and 
resuspended at a concentration of 1 × 106/ml. For priming, 10 ml 
of BMDM cell suspension were seeded in 100  mm dishes and 
treated with 1 ng/ml LPS.
generation of BMDcs
Bone marrow cells were cultured in RPMI 1640 complete medium 
supplemented with penicillin and streptomycin, 10% FBS, 20 ng/ml 
recombinant mouse GM-CSF and 5  ng/ml IL-4 for 6  days or 
10  ng/ml recombinant mouse GM-CSF and 1  ng/ml IL-4 for 
12  days. The 12-day-cultured BMDC were stimulated for 24  h 
with 100 ng/ml LPS and analyzed by flow cytometry.
isolation of Peritoneal Macrophages
Cells were isolated from the peritoneal cavity by lavage with 5 ml 
RPMI. Cells were washed in media prior to plating in 24-well 
plates in RPMI containing 10% FBS, penicillin, and streptomycin. 
After 2  h, non-adherent cells were washed away and adherent 
macrophages were treated with LPS in complete RPMI media 
for 48 h.
Flow cytometry
Single cell suspensions were Fc-receptor-blocked for 30 min at 
4°C with rat anti-mouse CD16/CD32 Ab in PBS with 1% FBS. 
Blocked cells were subsequently incubated with fluorophore-
conjugated primary Abs for 60 min at 4°C, prior to washing in 
PBS containing 1% FBS and 2 mM EDTA. Following surface 
staining, cells were washed and analyzed by flow cytometry, 
or were fixed with 2% formaldehyde in PBS and then washed/
permeabilized with BD perm/wash buffer (BD Biosciences), 
and stained with fluorophore-conjugated primary Abs for 
60 min at 4°C. Cells were washed and intracellular fluorescence 
analyzed using a FACS Canto II flow cytometer and FlowJo 
software.
intracellular TnF-α Production
1 ng/ml LPS-primed cells were stimulated with 100 ng/ml LPS 
for 7  h and monensin-containing GolgiStop (BD Biosciences) 
was added in the last 6  h of culture. After washing, cells were 
surface stained with biotinylated sheep anti-siglec-E Ab followed 
by streptavidin-APC. Cells were then fixed with the Cytofix/
Cytoperm solution (BD Biosciences) and incubated with 
PE-conjugated anti-mouse TNF-α Ab diluted in BD Perm/Wash 
buffer (BD Biosciences). Cells were analyzed by flow cytometry 
using a FACS Canto II with FlowJo software.
cytokine elisas
IL-6, RANTES, and IL-10 were measured in tissue culture super-
natants and sera using ELISA kits according to the manufacturer’s 
instructions and assay procedures (Peprotech).
Quantitative real-time Pcr
Total RNA was extracted using RNeasy mini kit (Qiagen). To 
quantify the gene expression, cDNA was synthesized using 
Omniscript RT kit (Qiagen). The sequences of the primers are 
shown below. Each PCR was performed in a 25  µl reaction 
mixture containing SYBR Green Universal master mix (Applied 
Biosystems). The final concentration of primers was 0.3 µM in 
each reaction. The thermal cycling conditions were as follows: 
10 min at 95°C, followed by 40 cycles of 15 s at 95°C, 30 s at 60°C, 
and 30 s at 72°C.
Siglec-E Forward GTC TCC ACA GAG CAG TGC AAC TTT ATC
Reverse TGG GAT TCA ACC AGG GGA TTC TGA G
Siglec-F Forward CCA CAG GAC CAC CCT CTC CTC
Reverse GGA CTT TAG TTC CTG TGT CAT CTC CC
Siglec-G Forward GCT GCT ACC TGA TAA AGA CAG TGC C
Reverse TTT CCA ATT CCG AGC CAG GGA CC
GAPDH Forward CAA CTC CCA CTC TTC CAC CTT CG
Reverse GTA GGG AGG GCT CAG TGT TGG G
Treatment of Mice with lPs
Age- and sex-matched mice were injected intraperitoneally with 
15  µg LPS [ultrapure E. coli 0111:B4 (Invivogen)]. After 3  h, 
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mice were euthanized, blood was collected by cardiac puncture 
and serum samples were prepared for use in ELISA. In some 
experiments, livers and spleens were harvested and frozen for 
immunofluorescence staining and microscopy.
infection of Mice with Salmonella
Sex- and age-matched 9- to 15-week-old mice were infected by 
intravenous injection of Salmonella enterica serovar Typhimurium 
strain M525P suspensions in a volume of 0.2 ml PBS. Cultures 
were grown from single colonies in 10  ml LB broth incubated 
overnight without shaking at 37°C, then diluted in PBS to the 
appropriate concentration for inoculation. The infective dose was 
enumerated by plating dilutions onto LB agar plates. Mice were 
killed by exposure to a rising concentration of carbon dioxide, 
and death confirmed by cervical dislocation. Livers and spleens 
were aseptically removed and homogenized in sterile water 
using a Precellys 24 homogenizer. The resulting homogenate was 
diluted in a 10-fold series in PBS and LB agar pour plates were 
used to enumerate viable bacteria.
infection of Macrophages with Bacteria 
for Bacterial Uptake, Bactericidal activity, 
and Tlr4 endocytosis assays
To assess bacterial uptake, cells were infected with either 
S. Typhimurium strain M525P or E. coli-GFP for 30  min. After 
infection, the cells were washed with PBS and analyzed by 
flow cytometry. For assessing bactericidal activity, the infected 
cells were further incubated for 60 min with medium contain-
ing 100  µg/ml gentamicin to kill extracellular bacteria. The 
medium was then replaced with 10 µg/ml gentamicin and bac-
tericidal activity was measured by harvesting cells at different 
time points and analyzing the decaying E. coli-GFP signal by 
flow cytometry. To assess TLR4 levels, cells were infected with 
E. coli-GFP for 1 h, stained with anti-TLR4 Ab and analyzed by 
flow cytometry.
siglec-e co-immunoprecipitation
Bone marrow-derived macrophages were primed with 1 ng/ml 
LPS for 3  days and lysed in 50  mM Tris–HCl, 150  mM NaCl, 
and 1% NP-40 with protease and phosphatase inhibitors. Lysates 
were subjected to immunoprecipitation with anti–siglec-E Ab. 
Immunoblots were probed with sheep anti-siglec-E Ab and Abs 
to SHP-1 and phosphotyrosine followed by HRP-conjugated 
secondary Abs followed by ECL autoradiography.
sP3 Processing for Quantitative 
Proteomics
Bone marrow-derived macrophages were primed with 1  ng/ml 
LPS for 3  days and stimulated with 100  ng/ml LPS for 7  h. 
Monensin-containing GolgiStop (BD Biosciences) was added 
for the last 6 h of culture. After washing, cells were lysed in lysis 
buffer (4% SDS, 50  mM TEAB pH 8.5, 10  mM TCEP), boiled 
and sonicated with a BioRuptor (30 cycles: 30  s on, 30  s off) 
before alkylation with 20  mM iodoacetamide for 1  h at room 
temperature in the dark. Lysates were subjected to the SP3 protein 
clean-up procedure (22), eluted into digestion buffer (0.1% SDS, 
50 mM TEAB pH 8.5, 1 mM CaCl2) and digested with trypsin at 
a 1:50 (enzyme:protein) ratio. TMT labeling and peptide clean-
up were performed according to the SP3 protocol. Samples were 
eluted into 2% DMSO, combined, and dried under vacuum. TMT 
samples were fractionated using offline high pH reverse-phase 
chromatography. Peptides were separated, concatenated to 22 
fractions, dried and peptides redissolved in 5% formic acid and 
analyzed by LC-MS.
Proteomics Quantification and 
Bioinformatics analysis
Four biological replicates from four independent biological 
samples were processed for proteomic analysis (22). The raw 
mass spectrometric data were loaded into MaxQuant (version 
1.5.3.30) (23), using the Andromeda search engine software 
(24). Enzyme specificity was set to that of trypsin/P, allowing for 
cleavage of N-terminal to proline residues and between aspartic 
acid and proline residues. Other parameters used were as fol-
lows: (i) variable modifications—methionine oxidation, protein 
N-acetylation; (ii) fixed modifications, cysteine carbamidometh-
ylation; (iii) database: Uniprot—mouse (downloaded 130501, 
50800 sequences); (iv) labels: 10-plex TMT (v) MS/MS tolerance: 
FTMS- 50ppm, ITMS-0.5  Da; (vi) minimum peptide length, 
7; (vii) maximum missed cleavages, 2; and (viii) and (ix) PSM 
and Protein false discovery rate, 1%. For bioinformatic analysis, 
Reporter ion intensities (corrected) results from MaxQuant were 
imported into Perseus software (version 1.5.1.6). The normalized 
corrected reporter ion intensities for each label were used to cal-
culate ratios and all “Contaminant,” “Reverse” and “Only identi-
fied by site” proteins were removed from the data. Proteins above 
twofold change [log2(2) = 1], proteins with nominal p-value less 
than 0.05 [−log10(0.05) = 1.301] were considered as differentially 
expressed proteins. All bioinformatics analyses were performed 
with the Perseus software of the MaxQuant computational 
platform (23–25). GO over representation enrichment analysis 
was done using WEB-based Gene SeT AnaLysis Toolket and 
geneontology database (26). The mass spectrometry proteomics 
data have been deposited to the ProteomeXchange Consortium 
via the PRIDE (27) partner repository with the dataset identifier 
PXD008406.
statistics
Statistical significance was determined using the two-tailed 
Student’s t-test or non-parametric Mann–Whitney rank-sum 
test. All experiments were performed at least twice. p Values of 
<0.05 were considered significant.
resUlTs
siglec-e is Upregulated on Macrophages 
by lPs In Vivo and In Vitro, but Does not 
regulate Production of inflammatory 
Mediators
To study the physiological role of siglec-E in regulating LPS-
TLR4-driven inflammatory responses, we used siglec-E-deficient 
FigUre 1 | Siglec-E expression on tissue macrophages and bone marrow-derived macrophages (BMDM) is upregulated following lipopolysaccharide (LPS) 
treatment. (a) Wild-type (WT), KO1, and R126D mice were injected with 15 µg LPS or PBS intraperitoneally. After 3 h, animals were euthanized and tissue 
samples collected and frozen. Liver cryostat sections were labeled with sheep anti-siglec-E Ab directly labeled with Alexa 488 and anti-siglec-1 Abs SER-4  
and 3D6 followed by anti-rat Alexa 647. Sections were also stained with DAPI to reveal nuclei. Siglec-E is expressed on Kupffer cells, which co-express 
siglec-1, and is upregulated following LPS stimulation in WT but not KO1 or R126D mice. Green dots in the anti-siglec-E stained KO1 and R126D sections  
are due to non-specific binding of the antibody (Ab). The scale bar represents 10 µm. (B) Siglec-E is expressed at low levels on BMDM and strongly 
upregulated following 3 days culture in 1 ng/ml LPS. (c) Siglec-E is constitutively phosphorylated in LPS-stimulated BMDM. WT and KO2 BMDM were  
treated for 3 days with 1 ng/ml LPS and the upregulated siglec-E was immunoprecipitated (IP) using sheep ant-siglec-E Ab and immunoblotted (IB) for 
phosphotyrosine, SHP-1 and siglec-E.
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mice generated by three different approaches as described in 
our previous reports (13, 21). First, siglec-E KO1 mice (referred 
to as KO1) were generated in 129 embryonic stem (ES) cells fol-
lowing replacement of exons 1 and 2 with a neomycin cassette 
and backcrossed for more than 15 generations onto the C57BL/6J 
and Balb/c genetic backgrounds. Second, siglec-E “knockin” 
mice (referred to as R126D) were generated in C57BL/6 ES cells 
by introducing a targeted mutation, R126D, to destroy the sialic 
acid-binding site of siglec-E (13). R126D were shown previously 
not to express siglec-E protein at detectable levels due to effects 
on gene transcription (13). Third, siglec-E KO2 mice (referred 
as KO2) are a complete knock-out of siglec-E on a C57BL/6J 
background, generated by further crossing R126D mice with 
transgenic (Nes-cre)1Wme/J (Bal1 cre) mice to partially delete 
the loxP-flanked allele (21). As described previously, all mouse 
lines were born at normal Mendelian frequencies and were 
viable, with no alterations in leukocyte subpopulations com-
pared with their matched WT controls.
On cryostat sections, siglec-E was shown to be expressed in 
tissue macrophages including liver Kupffer cells (Figure  1A) 
and splenic red pulp macrophages (data not shown) and was 
strongly upregulated on Kupffer cells following injection of 
mice with 15  µg LPS (Figure  1). As expected, siglec-E was 
undetectable in tissues of siglec-E-deficient mice (Figure 1A). 
To study the signaling functions of siglec-E in macrophages, 
we used BMDM grown in M-CSF or in L929 cell conditioned 
medium as a source of M-CSF. These cells expressed very 
low levels of siglec-E but this could be strongly increased by 
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cultivation for 3 days in low dose, 1 ng/ml LPS (Figure 1B). 
This low concentration of LPS was shown previously not to 
tolerize macrophages to a subsequent high-dose challenge of 
100  ng/ml LPS (28). Immunoprecipitation of siglec-E from 
1  ng/ml LPS-primed BMDM cells revealed that siglec-E was 
constitutively tyrosine-phosphorylated and associated with 
endogenous SHP-1 (Figure 1C).
To investigate whether siglec-E could inhibit TLR4-driven 
inflammatory responses, LPS-primed BMDM were challenged 
for 7 h with 100 ng/ml LPS, with GolgiStop (monensin) added 
for the last 6 h post LPS stimulation to trap secreted inflammatory 
proteins. This led to strong induction of TNF-α as measured by 
intracellular flow cytometry (Figure 2A). However, no differences 
were seen comparing WT and siglec-E-deficient macrophages. To 
determine whether siglec-E could modulate other TLR4-driven 
cytokine responses at the later time point of 48-h post LPS treat-
ment, ELISA was used to measure IL-6, IL-10, and RANTES in 
tissue culture supernatants, but no significant differences were 
seen comparing WT and siglec-E-deficient BMDM (Figure 2B). 
Similar observations were made using resident peritoneal mac-
rophages that constitutively express siglec-E (Figure 2C). Finally, 
we asked whether siglec-E-deficient mice exhibited exaggerated 
cytokine responses at 3 h following intraperitoneal injection of 
LPS. Surprisingly, we saw reduced IL-6 and IL-10 responses in 
the sera of KO1 mice, but no differences were seen in E126D mice 
(Figure 3).
To check whether other ITIM-containing CD33-related siglecs 
were expressed in LPS-treated macrophages to compensate for 
the loss of siglec-E expression, we performed quantitative RT-PCR 
on macrophage lysates and analyzed expression of mRNAs 
encoding siglecs-E, -F, and -G, which are the only ITIM-bearing 
CD33-related siglecs in mice (Figure  4). As a positive control 
for siglecs-F and -G, which are mainly expressed in eosinophils 
and B cells, respectively, we used mouse bone marrow cells that 
showed the expected signals. However, while siglec-E mRNA 
was strongly upregulated in LPS-treated WT macrophages, there 
was no evidence for upregulation of mRNAs for siglecs-F and -G 
which remained at low or undetectable levels (Figure  4). 
Therefore, the failure of siglec-E to suppress TLR4 signaling can-
not be explained by compensatory upregulation of other related 
inhibitory siglecs.
Quantitative proteomics was next used as an unbiased 
approach to determine if additional LPS-induced inflamma-
tory mediators could be regulated by expression of siglec-E in 
macrophages (Figure 5). A number of secretory inflammatory 
cytokines (TNF, Il16, Il1b, Il18, and Il19) and chemokines 
(Ccl2, Ccl3, Ccl4, Ccl5, Ccl6, Ccl7, Ccl9, Ccl12, Cxcl2, Cxcl3, 
Cxcl10, Cxcl16, and Cxxc1) were detected in the proteome fol-
lowing 100 ng/ml LPS treatment (Table S1 in Supplementary 
Material). However, apart from Ccl7 which was reduced in 
KO2 macrophages, none of the other upregulated cytokines and 
chemokines showed any significant differences comparing pro-
teomes from WT and siglec-E-deficient BMDM (Figure 5A). 
Interestingly, the proteomics analysis revealed that WT 
and siglec-E-deficient BMDM exhibited many differentially 
regulated proteins not implicated in LPS-induced inflamma-
tion. Gene ontology enrichment analyses showed that these 
proteins were mainly associated with cellular features, such as 
membranes, vesicular transport, and cytoskeleton (Figure 5B).
siglec-e-Deficient BMDM are not 
Defective in Bacterial Uptake and Killing
The proteomic differences between WT and siglec-E KO mac-
rophages point to functions relating to endocytosis and endoso-
mal/lysosomal trafficking which could be relevant to bacterial 
uptake and/or bactericidal activity of macrophages (29–31). 
This possibility was also consistent with in vivo observations 
that siglec-E-deficient mice showed increased bacterial loads 
following infection with Salmonella Typhimurium (Figure 6). 
Therefore, to test the hypothesis that siglec-E contributed 
to uptake and killing of bacteria by macrophages, in  vitro 
infection studies were carried out using S. Typhimurium and 
E. coli (Figure 7). No differences in uptake of either bacteria 
were observed at 30  min after infection comparing WT and 
siglec-E-deficient BMDM (Figure 7A). In addition, no differ-
ences in bactericidal activity of macrophages were seen using 
E. coli–GFP and measuring loss of the GFP signal over a 6 h 
time course (Figure 7B).
siglec-e is not required for Tlr4 
endocytosis in BMDM, BMDc, splenic 
Macrophages, or splenic Dcs
Several studies have shown that LPS–CD14–TLR4–MD2 com-
plexes undergo endocytosis, leading to macrophage desensiti-
zation and tolerance (32–35). The endocytosed TLR4 initially 
activates TRIF–TRAM signaling in the early endosome and is 
later channeled to lysosomes and degraded through the ubiqui-
tin pathway to limit further signaling (36–38). Recent studies 
in DCs demonstrated a role for siglec-E in promoting TLR4 
endocytosis and downregulating TLR4-mediated inflamma-
tory responses following E. coli infection (1, 18). In view of our 
findings that siglec-E on macrophages does not seem to regulate 
TLR4 inflammatory signaling, we asked if siglec-E affects TLR4 
endocytosis in macrophages. Following E. coli-GFP infection 
of BMDM, TLR4 underwent endocytosis as reported by oth-
ers (Figure  8A). However siglec-E-deficient BMDM showed 
similar levels of TLR4 endocytosis (Figure 8A; Figure S1A in 
Supplementary Material). To check if the previously reported 
role of siglec-E in downregulating TLR4 was restricted to DCs, 
we also analyzed responses in BMDC (Figure 8A). Similar to 
BMDM, the BMDC showed strong downregulation of TLR4 on 
exposure to E. coli-GFP, but this was unaffected in cells prepared 
from siglec-E deficient mice (Figure 8A). We also asked whether 
siglec-E might regulate LPS-mediated TLR4 endocytosis. While 
low doses up to 1.0  ng/ml LPS did not affect TLR4 levels at 
the cell surface, higher doses such as 50 ng/ml led to reduced 
TLR4 expression that was similar in WT and siglec-E-deficient 
BMDM (Figures 8B,C; Figure S1B in Supplementary Material). 
Similar observations were made with splenic macrophages and 
splenic DCs incubated with E. coli-GFP though the overall 
levels of TLR4 endocytosis were low compared to in  vitro 
cultured BMDM and BMDC (Figure  8D; Figures S1C,D in 
Supplementary Material).
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FigUre 2 | Continued
FigUre 3 | Analysis of lipopolysaccharide (LPS)-dependent cytokine responses in siglec-E-deficient mice. (a) Wild-type (WT) and KO1 mice and (B) WT and 
R126D mice were injected with 15 µg ultrapure LPS or PBS intraperitoneally and blood collected at 3 h. IL-6 and IL-10 concentrations in sera were measured by 
ELISA. Data show means + 1 SD from pooled samples, derived from two independent experiments, with three to six mice in each experiment. Statistical analysis 
was performed using Mann–Whitney t-test, ***indicates significant differences between WT and KO1 mice, p < 0.0005.
FigUre 2 | Analysis of cytokine production by wild-type (WT) and siglec-E-deficient macrophages following lipopolysaccharide (LPS) treatment. (a) WT and 
siglec-E KO2 bone marrow-derived macrophages (BMDM) were primed with 1 ng/ml LPS to induce siglec-E expression, treated with or without 100 ng/ml 
LPS ± GolgiStop to trap secretory proteins and analyzed by flow cytometry for TNFα. Three independent biological replicates were performed for each genotype. 
(B) BMDM from WT and siglec-E-deficient mice were cultured in the presence of LPS for 2 days. (c) Resident peritoneal macrophages from WT and siglec-E-
deficient mice were cultured in the presence of LPS for 6 h. For (B,c), cytokine levels in supernatants were assessed by ELISA. Data show means + 1  
SD from a single experiment performed in triplicate and representative of two independent experiments. Statistical analyses were performed using  
Student’s t-test. *indicates p < 0.05.
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siglec-e is expressed by splenic Dc, 
splenic red Pulp Macrophages, and 
splenic granulocytes but is not  
expressed on BMDcs
Previous studies have reported siglec-E-dependent functional 
responses using BMDC, but they did not demonstrate siglec-E 
expression by these cells (1, 18). To address this, we analyzed 
siglec-E levels in BMDC generated from BM progenitor cells 
cultured for 6 days in GM-CSF and IL-4 (Figure 9). As reported 
by others, the 6-day-cultured BM  cells are a heterogeneous 
population containing granulocytes, macrophages, and DCs 
that can be readily distinguished using surface markers (39). In 
multiple experiments, we observed high siglec-E expression on 
Gr1-positive granulocytes, however, CD11c, MHCII double-
positive DCs consistently lacked siglec-E expression (Figure 9A; 
Figure S1E in Supplementary Material). When 12-day-cultured 
BMDC were matured with LPS, there was clear upregulation of 
MHC class II, but more than 94% of the mature DCs (MHCII 
high cells) lacked siglec-E expression (Figure 9B).
In comparison to BMDC, CD11c, MHCII double-positive 
DCs extracted from the spleen expressed low levels of siglec-E 
as observed previously (13). By contrast, F4/80-positive splenic 
macrophages and Gr-1-positive granulocytes expressed much 
higher levels of siglec-E (Figure 10).
DiscUssiOn
The focus of this study was to explore the role of siglec-E in regu-
lating TLR4-induced inflammatory responses in macrophages. 
Our approach was to use siglec-E-deficient mice generated by 
gene targeting in ES cells, which is a conventional methodology 
to determine protein function in the immune system. Using 
three different strains of siglec-E-deficient mice and matched 
WT controls, we were unable to demonstrate an important role 
for siglec-E in regulating inflammatory cytokines downstream of 
TLR4 activation, both in vitro and in vivo. We showed that this 
was not due to compensation by other closely related inhibitory 
siglecs in the siglec-E-deficient macrophages. However, quan-
titative proteomics revealed differences in the levels of many 
proteins shared by WT and siglec-E-deficient macrophages 
following LPS activation and we cannot exclude the possibility 
that some of these differences could mask siglec-E dependent 
effects on TLR4 signaling.
FigUre 4 | Other inhibitory CD33-related siglecs do not compensate for siglec-E deficiency in bone marrow-derived macrophages (BMDM). Relative gene 
expression of siglec-E, siglec-F, and siglec-G in BMDM untreated or stimulated with 10 ng/ml lipopolysaccharide (LPS) for 48 h from wild-type and siglec-E-deficient 
mice. Gene expression is shown relative to GAPDH, using untreated WT BMDM as calibrator. WT bone marrow cells were used as a control for siglecs-E, -F, and -G 
as they are expressed in developing neutrophils, eosinophils, and B cells, respectively, and show the expected gene expression profiles.
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In considering a potential role of siglec-E in regulating TLR4 
signaling, it is important to distinguish cis-interactions of siglec-
E with TLR4 (1, 18) and trans–interactions of siglec-E with other 
ligands. Cis-interactions occur through presentation of sialic 
acid ligands on neighboring glycoproteins and glycolipids. Their 
importance has been clearly documented in the case of CD22 
and siglec-G on B cells using genetic and biochemical approaches 
where CD22 has been shown to associate with other CD22 mol-
ecules and siglec-G has been shown to associate with the B cell 
receptor complex [reviewed in Ref. (11)]. Such cis-interactions 
play a key role in regulating the threshold of B cell activation 
to antigens and preventing autoimmunity. The evidence that 
siglec-E associates in cis with TLR4 was based on pull-down 
experiments and overlays using recombinant forms of siglecs 
FigUre 6 | Siglec-E-deficient mice show enhanced growth of Salmonella Typhimurium following intravenous infection. (a) Wild-type (WT) and KO1 mice on a 
Balb/c background and (B) WT and KO1 on a C57BL/6J background and R126D mice were infected with S. Typhimurium M525P and liver and spleen CFU 
determined from groups of 4–8 mice at the indicated time points. Data in (a) show mean values ± 1 SD and data in (B) show values for individual mice. Statistical 
analysis was performed by Student’s t-test: *p < 0.05; **p < 0.005; ***p < 0.0005.
FigUre 5 | Quantitative proteomics analysis of wild-type (WT) and KO2 bone marrow-derived macrophages (BMDM) activated by lipopolysaccharide (LPS).  
(a) Volcano plot showing proteomics data derived from four independent biological replicates. WT and KO2 BMDM cells were primed for 3 days with 1 ng/ml  
LPS and challenged with 100 ng/ml LPS + GolgiStop for 7 h and lysates subjected to quantitative proteomics. The inflammatory mediators are annotated in pink. 
Gapdh and histone variants are in green and cytokine receptors in blue. (B) GO analysis of proteins that are differentially regulated between WT and KO2 BMDM.
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FigUre 7 | Uptake and killing of bacteria by bone marrow-derived macrophages (BMDM) are not affected by siglec-E expression. (a) BMDM from wild-type (WT) 
and siglec-E-deficient mice were cultured for 3 days with 1 ng/ml LPS to upregulate siglec-E expression and incubated with S. Typhimurium M525P for 30 min at a 
ratio of 1:50 BMDM:bacteria. Bacterial uptake was analyzed by flow cytometry using anti-salmonella antibody (Ab) conjugated with Alexa-488 and siglec-E 
expression was measured using biotinylated sheep anti-siglec-E Ab followed by streptavidin-APC. (B) BMDM as above were incubated with E. coli-GFP for 30 min 
at a ratio of 1:20 BMDM:bacteria. Cells were washed and maintained in antibiotic media to kill extracellular bacteria and the bactericidal activity of BMDM was 
monitored at the indicated time points by flow cytometry. No differences were seen in bacterial uptake or killing activity. Bar charts in (a,B) show mean values + 1 
SD from three independent experiments.
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and TLRs, but no direct evidence that siglec-E associates with 
TLR4 in situ was provided (1). Experimentally induced trans-
interactions of siglec-E occur following Ab cross-linking (14), 
exposure of macrophages to nanoparticles coated with sialic 
acid ligands (17), or to pathogens displaying a high density of 
sialic acids on their surface (16), leading to siglec-E-dependent 
suppression of TLR signaling. In these cases, the trans-ligand-
induced clustering of siglec-E in the membrane is likely to drive 
strong ITIM phosphorylation and recruitment of effectors that 
could modulate TLR signaling through a number of pathways. 
Likewise, overexpression of siglecs in macrophage-like cell 
lines (15) could lead to non-physiological clustering and a 
FigUre 8 | Expression of siglec-E does not influence toll-like receptor 4 (TLR4) endocytosis in bone marrow-derived macrophages (BMDM) and bone marrow-derived 
dendritic cells (BMDC). (a) Wild-type (WT) and siglec-E-deficient BMDM cultured for 3 days in 1 ng/ml lipopolysaccharide (LPS) and BMDC were incubated with 
E. coli-GFP for 1 h a ratio of 1:10 and TLR4 and GFP expression determined by flow cytometry (B) WT and siglec-E-deficient BMDM were incubated with the indicated 
doses of LPS for 3 days and TLR4 expression determined by flow cytometry. (c) BMDM were incubated for 1 day without LPS or with 50 ng/ml LPS and TLR-4 and 
siglec-E levels determined by flow cytometry (D) Splenocytes from WT and siglec-E-deficient mice were incubated with E. coli-GFP at 1:10 ratio and gated on F4/80 
positive cells and CD11c, MHCII double-positive cells and expression of TLR4 determined by flow cytometry. Two independent biological replicates were performed for 
each genotype.
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FigUre 9 | Continued
similar outcome with respect to TLR-dependent signaling 
and suppression of pro-inflammatory cytokines. Based on the 
findings reported here, we propose that at physiological levels 
of siglec expression, stimulation of macrophages with LPS, in 
the absence of trans-ligand-induced siglec-E clustering, does 
not affect TLR4-dependent pro-inflammatory signaling. These 
observations are in line with a study showing that a sialic acid 
deletion mutant of Group B Streptococcus triggered similar 
amounts of TNF-α secretion in WT and siglec-E-deficient mac-
rophages (16) and also with a study using lentiviral-mediated 
knockdown of siglec-E that did not affect the TLR4-triggered 
inflammatory response (17). In both cases, siglec-E inhibited 
LPS- or pathogen-induced inflammatory responses only via 
trans-interactions.
Our results contradict the findings of Chen et al. and Wu et al. 
who showed that BMDC from siglec-E-deficient mice exhibited 
strongly exaggerated IL-6 and TNF-α secretion following LPS 
and E. coli stimulation (1, 18). Furthermore, Wu et al. showed 
that TLR4 endocytosis induced by uptake of E. coli in DC popu-
lations was defective in cells prepared from siglec-E-deficient 
mice. This is at odds with findings presented here, where there 
was no difference in TLR4 endocytosis in both macrophages and 
DCs. Furthermore, we showed that siglec-E is not expressed on 
the vast majority of immature and mature BMDC, a key issue 
that was not addressed in their publications. Even splenic DCs 
expressed very low levels of siglec-E compared to macrophages 
and neutrophils, suggesting that siglec-E is not a major regulatory 
receptor in these cells. It is noteworthy that the siglec-E-deficient 
FigUre 9 | Siglec-E is not expressed by bone marrow-derived dendritic cells (BMDC). (a) Wild-type (WT) and siglec-E-deficient bone marrow cells were cultured in 
20 ng/ml recombinant mouse GM-CSF and 5 ng/ml IL-4 for 6 days to generate BMDC and analyzed by flow cytometry for siglec-E expression on CD11c, MHCII 
double-positive cells and Gr-1 positive cells (B) BMDC were cultured in 10 ng/ml recombinant mouse GM-CSF and 1 ng/ml IL-4 and matured for 24 h using 100 ng/
ml lipopolysaccharide (LPS) or left untreated and analyzed by flow cytometry. CD11c positive BMDCs with high and low levels of MHC expression were gated and 
siglec-E levels analyzed on the different subsets. Two independent biological replicates were performed for each genotype.
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mice used in the studies of Chen et al. and Wu et al. were gener-
ated from 129 ES cells and backcrossed for three generations 
onto a C57BL/6 line resulting in less than 90% of the genome 
being derived from the C57BL/6 background. However, of more 
concern is the likely large number of “passenger genes” derived 
from 129 mice flanking the siglec-E locus that differ in protein 
sequence between siglec-E-deficient mice and the matched WT 
mice that could have strongly influenced the results of their 
studies. It is well established that many phenotypes ascribed to 
genes of interest are actually due to polymorphic passenger gene 
effects (40). This could also explain why the 129 ES-derived KO1 
mice used in the present study showed reduced IL-6 and IL-10 
responses to LPS in  vivo whereas no differences were seen in 
C57BL/6 ES-derived R126D mice. Further studies are required 
to reconcile these differences.
The most interesting outcome of our unbiased quantitative 
proteomics was the finding that WT and siglec-E-deficient 
macrophages challenged with high-dose LPS exhibit differ-
ences in levels of many proteins associated with membrane 
function, vesicular transport, and cytoskeleton. Although we 
did not see altered bacterial uptake or killing in  vitro, these 
protein differences might regulate aspects of macrophage 
function in situ that are important for host defense to infection 
and explain the reduced numbers of Salmonella seen here in 
WT mice compared to siglec-E-deficient mice. An additional 
attractive hypothesis is that siglec-E contributes to TLR4-
induced macrophage differentiation and/or polarization. The 
heterogeneity of resident macrophage populations in different 
tissues is well documented, although the physiological rel-
evance of this phenotypic heterogeneity within different tissue 
microenvironments is not completely understood (41). Several 
studies have shown that TLR agonists can drive polarization 
and cellular reprogramming in macrophages, monocytes, 
hematopoietic stem, and progenitor cells (42, 43). Induction 
FigUre 10 | Differential expression of siglec-E on splenic myeloid cell populations. Wild-type (WT) and siglec-E-deficient splenocytes were gated for dendritic cells 
(DCs) (CD11c, MHCII double-positive cells), macrophages (F480 positive cells), and granulocytes (Gr-1-positive cells) and analyzed for siglec-E expression by flow 
cytometry. Two independent biological replicates were performed for each genotype.
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of siglec-E by TLR4 activation could contribute to this pro-
cess, as we showed that the induced siglec-E is constitutively 
tyrosine phosphorylated and associated with protein tyrosine 
phosphatase SHP-1. Interestingly, SHP-1 has been shown to 
be one of the key players among several molecular pathways 
that control macrophage polarization (44). Therefore, siglec-E-
mediated activation of SHP-1 in macrophages could target key 
downstream substrates that modulate macrophage differentia-
tion and TLR reprogramming, leading to a siglec-E-dependent 
phenotype. Our future studies will attempt to investigate the 
significance of this putative differentiation pathway for host 
defense and homeostasis.
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FigUre s1 | Expression of siglec-E does not influence toll-like receptor 4 
(TLR4) endocytosis in bone marrow-derived macrophages (BMDM) and 
bone marrow-derived dendritic cells (BMDC). (a) Wild-type (WT) and 
siglec-E-deficient BMDM were cultured for 3 days in 1 ng/ml 
lipopolysaccharide (LPS) and incubated with E. coli-GFP for 1 h at a ratio of 
1:10 and TLR4 and GFP expression determined by flow cytometry.  
(B) BMDM were incubated for 1 day without LPS or with 50 ng/ml LPS and 
TLR4 levels determined by flow cytometry. (c,D) Splenocytes from WT and 
siglec-E-deficient mice were incubated with E. coli-GFP at 1:10 ratio and 
gated on F4/80 positive cells (c) and CD11c, MHCII double-positive cells 
(D) and TLR4 levels determined by flow cytometry. (e) Siglec-E is not 
expressed by BMDC. WT and siglec-E-deficient bone marrow cells were 
cultured in recombinant mouse GM-CSF and IL-4 for 6 days to generate 
BMDC and analyzed by flow cytometry for siglec-E expression on CD11c, 
MHCII double-positive cells. Staining for KO cells represents non-specific 
binding of the anti-siglec-E mAb. In (a–e), data show means + 1 SD from 
two biological replicates.
TaBle s1 | Quantitative proteomics data comparing WT and siglec-E-
deficient macrophages stimulated with 100 ng/ml LPS. Data show log2 
intensity values for 6,791 proteins identified in four independent biological 
replicates. Proinflammatory factors that are not significantly different 
comparing WT and siglec-E-deficient macrophages are highlighted in 
orange and proteins that are altered significantly are in green. Those 
increased in WT versus siglec-E-deficient macrophages are in dark blue, 
whereas those decreased in WT versus siglec-E-deficient macrophages are 
in pale blue.
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